Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

U.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

The phase 1 study tested autogene cevumeran (BNT122, RO7198457), a therapeutic mRNA cancer vaccine developed and researched through a collaboration between BioNTech, an immunotherapy company, and ...

A new im­munol­o­gy biotech closed its Se­ries A, and it’s backed by in­vestors in­tri­cate­ly fa­mil­iar with the in­dus­try.

Investors might want to bet on BioNTech SE Sponsored ADR (BNTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

U.S. FDA places BioNTech's malaria vaccine study on clinical hold The U.S. Food and Drug Administration has placed a clinical hold on BioNTech's early-to-mid stage trial of an experimental malaria ...

MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus ...